Article
Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
BMC cancer - 26 Apr 2023
Lau David K, Fong Caroline, Arouri Faten, Cortez Lillian, Katifi Hannah, Gonzalez-Exposito Reyes, Razzaq Muhammad Bilal, Li Su, Macklin-Doherty Aislinn, Hernandez Monica Arenas, Hubank Michael, Fribbens Charlotte, Watkins David, Rao Sheela, Chau Ian, Cunningham David, Starling Naureen
Abstract excerpt
BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolism of fluoropyrimidines. Variations in the encoding DPYD gene are associated with severe fluoropyrimidine toxicity and up-front dose reductions are recommended. We conducted a retrospective study to evaluate the impact of implementing DPYD variant testing for patients with gastrointestinal cancers in routine clinical practice in a...
Topics
Join the communities discussing this publication.